Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925

British Journal of Cancer

Volumn 110, Issue 12, 2014, Pages 2896-2904

  Yang, X ^a,b   Yang, P ^a   Shen, J ^a   Osaka, E ^a   Choy, E ^a   Cote, G ^a   Harmon, D ^a   Zhang, Z ^b   Mankin, H ^a   Hornicek, F J ^a   Duan, Z ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Drug resistance; NSC23925; Osteosarcoma; Paclitaxel; Pgp

Indexed keywords

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; OSTEOSARCOMA; P-GLYCOPROTEIN; PACLITAXEL; PIPERIDINES; QUINOLINES;

EID: 84902533342     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.254     Document Type: Article

References (43)

1. Agarwal R, Kaye SB (2003) Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3(7): 502-516. (Pubitemid 37328838
2. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, Schiffer CA, Bloomfield CD, Larson RA (2002) Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100(4): 1224-1232. (Pubitemid 34864276
3. Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, Meadows B, Stein WD, Choyke P, Balis F, Figg WD, Fojo T (2004) A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res 10(14): 4724-4733. (Pubitemid 38955523
4. Batrakova EV, Kabanov AV (2008) Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 130(2): 98-106
5. Batrakova EV, Kelly DL, Li S, Li Y, Yang Z, Xiao L, Alakhova DY, Sherman S, Alakhov VY, Kabanov AV (2006) Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: Pluronic P85. Mol Pharm 3(2): 113-123. (Pubitemid 43672247
6. Bodey B, Taylor CR, Siegel SE, Kaiser HE (1995) Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression. Anticancer Res 15(6B): 2461-2468
7. Chano T, Mori K, Scotlandi K, Benini S, Lapucci C, Manara MC, Serra M, Picci P, Okabe H, Baldini N (2004) Differentially expressed genes in multidrug resistant variants of U-2 OS human osteosarcoma cells. Oncol Rep 11(6): 1257-1263
8. Chou AJ, Geller DS, Gorlick R (2008) Therapy for osteosarcoma: Where do we go from here?. Paediatr Drugs 10(5): 315-327
9. Chou AJ, Gorlick R (2006) Chemotherapy resistance in osteosarcoma: Current challenges and future directions. Expert Rev Anticancer Ther 6(7): 1075-1085. (Pubitemid 44203385
10. Cocker HA, Tiffin N, Pritchard-Jones K, Pinkerton CR, Kelland LR (2001) In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. Clin Cancer Res 7(10): 3193-3198
11. Decaudin D, Castedo M, Nemati F, Beurdeley-Thomas A, De Pinieux G, Caron A, Pouillart P, Wijdenes J, Rouillard D, Kroemer G, Poupon MF (2002) Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res 62(5): 1388-1393. (Pubitemid 34407797
12. Dieudonne FX, Marion A, Hay E, Marie PJ, Modrowski D (2010) High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells. Cancer Res 70(13): 5399-5408
13. Duan Z, Choy E, Hornicek FJ (2009a) NSC23925, identified in a highthroughput cell-based screen, reverses multidrug resistance. PLoS One 4(10): E7415
14. Duan Z, Choy E, Jimeno JM, Cuevas Cdel M, Mankin HJ, Hornicek FJ (2009b) Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. Cancer Chemother Pharmacol 63(6): 1121-1129
15. Duan Z, Li X, Huang H, Yuan W, Zheng SL, Liu X, Zhang Z, Choy E, Harmon D, Mankin H, Hornicek F (2012) Synthesis and evaluation of (2-(4-methoxyphenyl)- 4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer. J Med Chem 55(7): 3113-3121
16. Gandhi L, Harding MW, Neubauer M, Langer CJ, Moore M, Ross HJ, Johnson BE, Lynch TJ (2007) A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer 109(5): 924-932. (Pubitemid 46333534
17. Gillet JP, Gottesman MM (2010) Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596: 47-76
18. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2(1): 48-58. (Pubitemid 37328807
19. Gupta SC, Patchva S, Koh W, Aggarwal BB (2012) Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 39(3): 283-299
20. Higgins CF (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature 446(7137): 749-757
21. Kang MH, Figg WD, Ando Y, Blagosklonny MV, Liewehr D, Fojo T, Bates SE (2001) The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin Cancer Res 7(6): 1610-1617. (Pubitemid 32708626
22. Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE (2011) A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 17(3): 569-580
23. Kobayashi E, Iyer AK, Hornicek FJ, Amiji MM, Duan Z (2012) Lipidfunctionalized dextran nanosystems to overcome multidrug resistance in cancer: A pilot study. Clin Orthop Relat Res 471(3): 915-925
24. Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Baer MR, Hars V, Maharry K, Hoke E, Vardiman JW, Bloomfield CD, Larson RA (2010) P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 116(9): 1413-1421
25. Lhomme C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, Baekelandt MM, Gordon AN, Fracasso PM, Mietlowski WL, Jones GJ, Dugan MH (2008) Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 26(16): 2674-2682
26. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK (2007) Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 13(11): 3423-3430. (Pubitemid 46944931
27. Marina N, Gebhardt M, Teot L, Gorlick R (2004) Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9(4): 422-441. (Pubitemid 39014554
28. Minderman H, O'Loughlin KL, Pendyala L, Baer MR (2004) VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 10(5): 1826-1834. (Pubitemid 38435574
29. O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, Dahl GV (2010) Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer 54(5): 694-702
30. Okada T, Tanaka K, Nakatani F, Sakimura R, Matsunobu T, Li X, Hanada M, Nakamura T, Oda Y, Tsuneyoshi M, Iwamoto Y (2006) Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells. Int J Cancer 118(1): 90-97. (Pubitemid 41681583
31. Ozben T (2006) Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 580(12): 2903-2909
32. Ryu K, Susa M, Choy E, Yang C, Hornicek FJ, Mankin HJ, Duan Z (2010) Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway. BMC Cancer 10: 187
33. Sakamoto A, Iwamoto Y (2008) Current status and perspectives regarding the treatment of osteo-sarcoma: Chemotherapy. Rev Recent Clin Trials 3(3): 228-231
34. Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, Charpentier D (2002) A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 86(3): 302-310. (Pubitemid 35425526
35. Sharma AK, Zhang L, Li S, Kelly DL, Alakhov VY, Batrakova EV, Kabanov AV (2008) Prevention of MDR development in leukemia cells by micelleforming polymeric surfactant. J Control Release 131(3): 220-227
36. Shukla S, Ohnuma S, Ambudkar SV (2011) Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets 12(5): 621-630
37. Susa M, Iyer AK, Ryu K, Choy E, Hornicek FJ, Mankin H, Milane L, Amiji MM, Duan Z (2010) Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 5(5): E10764
38. Suto R, Abe Y, Nakamura M, Ohnishi Y, Yoshimura M, Lee YH, Imanishi T, Yamazaki H, Kijima H, Tokunaga T, Oshika Y, Hiraoka N, Tamaoki N, Fukuda H, Ueyama Y (1998) Multidrug resistance mediated by overexpression of P-glycoprotein in human osteosarcoma in vivo. Int J Oncol 12(2): 287-291. (Pubitemid 28064849
39. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3): 219-234. (Pubitemid 43336035
40. Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW (2007) Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res 67(9): 4425-4433. (Pubitemid 46815092
41. Yen WC, Corpuz MR, Prudente RY, Cooke TA, Bissonnette RP, Negro-Vilar A, Lamph WW (2004) A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer. Clin Cancer Res 10(24): 8656-8664. (Pubitemid 40053434
42. Yen WC, Lamph WW (2006) A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer. Prostate 66(3): 305-316
43. Zatelli MC, Luchin A, Tagliati F, Leoni S, Piccin D, Bondanelli M, Rossi R, degli Uberti EC (2007) Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr Relat Cancer 14(4): 1029-1038. (Pubitemid 351252434.